GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4Results posted

Impact of Liraglutide 3.0 on Body Fat Distribution

Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease

Lead sponsor

University of Texas Southwestern Medical Center

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

235

actual

Study population

Metabolic syndrome, Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Visceral fat, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03038620

Org study IDSTU 122015-044

Timeline

Milestones

Study first posted2017-01-31estimated

Primary completion2020-10-13actual

Study completion2020-10-13actual

Last update posted2021-11-19actual

Results first posted2021-11-19actual

Study start2017-01actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Metabolic syndromeObesity / overweight

Eligibility

Who can enroll

Minimum age35 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Age ≥ 35 years

•Able to provide informed consent

•BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with metabolic syndrome

•Metabolic syndrome is defined as at least three of the following:3

1. waist circumference > 102 cm (40 in) in men and 88 cm (35 in) in women

2. triglycerides > 150 mg/dL or on treatment for hypertriglyceridemia

3. HDL cholesterol < 40 mg/dL in men and < 50 mg/dL in women

4. blood pressure > 130/85 mmHg or on treatment for hypertension

5. fasting glucose > 100 mg/dL

Exclusion criteria

•Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists (including liraglutide, exenatide or others as they become available), dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin within the last 3 months.

•Receipt of any anti-obesity drug or supplement within 1 month prior to screening for this trial.

•Self-reported or clinically documented history of significant fluctuations (>5% change) in weight within 3 months prior to screening for this trial.

•History of diabetes mellitus (type 1 or 2) or on treatment with anti-diabetes medication.

•History of chronic pancreatitis or idiopathic acute pancreatitis (current or prior history).

•History of gallbladder disease (cholelithiasis or cholecystitis).

•Chronic kidney disease stage III or greater (eGFR<60 mL/min).

•Obesity induced by other endocrinologic disorders (e.g. Cushing Syndrome).

•Current or history of treatment with medications that may cause significant weight gain, within 1 month prior to screening for this trial, including systemic corticosteroids (except for a short course of treatment, i.e., 7- 10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g., imipramine, amitryptiline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium).

•Diet attempts using herbal supplements or over-the-counter medications within 1 month prior to screening for this trial.

•Current participation in an organized weight reduction program or within the last 1 month prior to screening for this trial.

•Participation in a clinical trial within the last 3 months prior to screening for this trial.

•Familial or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.

•Personal history of non-familial medullary thyroid carcinoma.

•History of Major Depressive Disorder within the last 2 years.

•History of other severe psychiatric disorders, e.g., schizophrenia, bipolar disorder.

•Any lifetime history of a suicide attempt.

•A history of any suicidal behavior in the last month prior to randomization.

•Surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of the Investigator.

•Known or suspected hypersensitivity to trial product(s) or related product(s).

•Known or suspected abuse of alcohol or narcotics.

•Language barrier, mental incapacity, unwillingness or inability to understand.

•Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. These include abstinence and the following methods: diaphragm with spermicide, condom with spermicide (by male partner), intrauterine device, sponge, spermicide, Norplant®, Depo-Provera® or oral contraceptives.

Endpoints (74)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Cardiometabolic biomarkers

MASH / liver

Heart failure

Safety / tolerability / PK

Other (unclassified)

Weight & body composition

40 endpoints

Primary/registry result

Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI

Time frame:Baseline, 40 weeks

Visceral fat, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percentage of reduction in VAT	95% CI
Liraglutide 3.0 mg	12.49	10.4 – 14.6
Placebo	1.63	-1.62 – 4.88

Primary/protocol endpoint

Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI

Time frame:Baseline, 40 weeks

Visceral fat, change

percent change from baseline, improvement

Secondary/registry result

Absolute Reduction in Visceral Adipose Tissue Volume

Time frame:Baseline, 40 weeks

Visceral fat, change

change from baseline, improvement

Posted result

Group	Value (mean), Liters	95% CI
Liraglutide 3.0 mg	0.53	—
Placebo	0.10	—

Secondary/registry result

Relative Percent Reduction in Body Weight

Time frame:Baseline, 40 weeks

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	6.59	—
Placebo	1.19	—

Secondary/registry result

Absolute Reduction in Body Weight

Time frame:Baseline, 40 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (mean), Kilograms	95% CI
Liraglutide 3.0 mg	6.75	—
Placebo	1.3	—

Secondary/registry result

Relative Percent Reduction in Waist Circumference

Time frame:Baseline, 40 weeks

Waist circumference, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	6.90	—
Placebo	4.16	—

Secondary/registry result

Absolute Reduction in Waist Circumference

Time frame:Baseline, 40 weeks

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (mean), cm	95% CI
Liraglutide 3.0 mg	7.4	—
Placebo	4.6	—

Secondary/registry result

Relative Percent Reduction in Total Body Adipose Tissue

Time frame:Baseline, 40 weeks

Total fat mass

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	9.59	—
Placebo	0.95	—

Secondary/registry result

Absolute Reduction in Total Body Adipose Tissue

Time frame:Baseline, 40 weeks

Total fat mass

change from baseline, improvement

Posted result

Group	Value (mean), Liters	95% CI
Liraglutide 3.0 mg	3.76	—
Placebo	0.42	—

Secondary/registry result

Relative Percent Reduction in Abdominal Subcutaneous Adipose Tissue

Time frame:Baseline, 40 weeks

Subcutaneous fat, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	9.87	—
Placebo	0.77	—

Secondary/registry result

Absolute Reduction in Abdominal Subcutaneous Adipose Tissue

Time frame:Baseline, 40 weeks

Subcutaneous fat, change

change from baseline, improvement

Posted result

Group	Value (mean), Liters	95% CI
Liraglutide 3.0 mg	1.52	—
Placebo	0.15	—

Secondary/registry result

Relative Percent Reduction in Lower Body Subcutaneous Adipose Tissue

Time frame:Baseline, 40 weeks

Subcutaneous fat, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	9.95	—
Placebo	1.29	—

Secondary/registry result

Absolute Reduction in Lower Body Subcutaneous Adipose Tissue

Time frame:Baseline, 40 weeks

Subcutaneous fat, change

change from baseline, improvement

Posted result

Group	Value (mean), Liters	95% CI
Liraglutide 3.0 mg	1.51	—
Placebo	0.19	—

Secondary/registry result

Relative Percent Reduction in Total Body Lean Volume

Time frame:Baseline, 40 weeks

Lean mass

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	2.47	—
Placebo	0.90	—

Secondary/registry result

Absolute Reduction in Total Body Lean Volume

Time frame:Baseline, 40 weeks

Lean mass

change from baseline, improvement

Posted result

Group	Value (mean), Liters	95% CI
Liraglutide 3.0 mg	0.54	—
Placebo	0.17	—

Secondary/registry result

Relative Percent Reduction in Total Thigh Muscle Volume

Time frame:Baseline, 40 weeks

Lean mass

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	3.48	—
Placebo	0.68	—

Secondary/registry result

Absolute Reduction in Total Thigh Muscle Volume

Time frame:Baseline, 40 weeks

Lean mass

change from baseline, improvement

Posted result

Group	Value (mean), Liters	95% CI
Liraglutide 3.0 mg	0.35	—
Placebo	0.06	—

Secondary/registry result

Relative Percent Reduction in Mean Anterior Thigh Muscle Fat Infiltration Percent

Time frame:Baseline,40 weeks

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	2.81	—
Placebo	-0.29	—

Secondary/registry result

Absolute Reduction in Mean Anterior Thigh Muscle Fat Infiltration Percent

Time frame:Baseline,40 weeks

change from baseline, improvement

Posted result

Group	Value (mean), percentage of fat infiltration	95% CI
Liraglutide 3.0 mg	0.23	—
Placebo	0.01	—

Secondary/registry result

Change From Baseline in VAT/SAT Ratio

Time frame:Baseline, 40 weeks

change from baseline, improvement

Posted result

Group	Value (mean), ratio	95% CI
Liraglutide 3.0 mg	0.01	—
Placebo	0	—

Secondary/registry result

Change From Baseline in Total Fat/Fat-free Mass Ratio

Time frame:Baseline, 40 weeks

change from baseline, improvement

Posted result

Group	Value (mean), ratio	95% CI
Liraglutide 3.0 mg	-7.23	—
Placebo	0.01	—

Secondary/protocol endpoint

Absolute Reduction in Visceral Adipose Tissue Volume

Time frame:Baseline, 40 weeks

Visceral fat, change

change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Reduction in Body Weight

Time frame:Baseline, 40 weeks

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Body Weight

Time frame:Baseline, 40 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Reduction in Waist Circumference

Time frame:Baseline, 40 weeks

Waist circumference, change

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Waist Circumference

Time frame:Baseline, 40 weeks

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Reduction in Total Body Adipose Tissue

Time frame:Baseline, 40 weeks

Total fat mass

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Total Body Adipose Tissue

Time frame:Baseline, 40 weeks

Total fat mass

change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Reduction in Abdominal Subcutaneous Adipose Tissue

Time frame:Baseline, 40 weeks

Subcutaneous fat, change

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Abdominal Subcutaneous Adipose Tissue

Time frame:Baseline, 40 weeks

Subcutaneous fat, change

change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Reduction in Lower Body Subcutaneous Adipose Tissue

Time frame:Baseline, 40 weeks

Subcutaneous fat, change

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Lower Body Subcutaneous Adipose Tissue

Time frame:Baseline, 40 weeks

Subcutaneous fat, change

change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Reduction in Total Body Lean Volume

Time frame:Baseline, 40 weeks

Lean mass

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Total Body Lean Volume

Time frame:Baseline, 40 weeks

Lean mass

change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Reduction in Total Thigh Muscle Volume

Time frame:Baseline, 40 weeks

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Total Thigh Muscle Volume

Time frame:Baseline, 40 weeks

change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Reduction in Mean Anterior Thigh Muscle Fat Infiltration Percent

Time frame:Baseline,40 weeks

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Mean Anterior Thigh Muscle Fat Infiltration Percent

Time frame:Baseline,40 weeks

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in VAT/SAT Ratio

Time frame:Baseline, 40 weeks

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Total Fat/Fat-free Mass Ratio

Time frame:Baseline, 40 weeks

change from baseline, improvement

Glycemic / diabetes

12 endpoints

Secondary/registry result

Relative Percent Change in Fasting Blood Glucose

Time frame:Baseline, 40 weeks

Fasting glucose, change

percent change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	-5.62	—
Placebo	0.83	—

Secondary/registry result

Relative Percent Change in Insulin

Time frame:Baseline, 40 weeks

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	20.58	—
Placebo	7.73	—

Secondary/registry result

Relative Percent Change in HOMA-IR

Time frame:Baseline, 40 weeks

HOMA-IR (insulin sensitivity)

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	15.35	—
Placebo	11.85	—

Secondary/registry result

Absolute Change in Fasting Blood Glucose

Time frame:Baseline,40 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (mean), mg/dL	95% CI
Liraglutide 3.0 mg	-6.49	—
Placebo	-0.22	—

Secondary/registry result/low confidence

Absolute Change in Insulin

Time frame:Baseline, 40 weeks

change from baseline, improvement

Posted result

Group	Value (mean), mIU/L	95% CI
Liraglutide 3.0 mg	0.75	—
Placebo	-1.48	—

Secondary/registry result

Absolute Change in HOMA-IR

Time frame:Baseline, 40 weeks

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Posted result

Group	Value (mean), Molar units	95% CI
Liraglutide 3.0 mg	-0.15	—
Placebo	-0.69	—

Secondary/protocol endpoint

Relative Percent Change in Fasting Blood Glucose

Time frame:Baseline, 40 weeks

Fasting glucose, change

percent change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Relative Percent Change in Insulin

Time frame:Baseline, 40 weeks

percent change from baseline, improvement

Secondary/protocol endpoint

Relative Percent Change in HOMA-IR

Time frame:Baseline, 40 weeks

HOMA-IR (insulin sensitivity)

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Change in Fasting Blood Glucose

Time frame:Baseline,40 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Absolute Change in Insulin

Time frame:Baseline, 40 weeks

change from baseline, improvement

Secondary/protocol endpoint

Absolute Change in HOMA-IR

Time frame:Baseline, 40 weeks

HOMA-IR (insulin sensitivity)

change from baseline, improvement

MASH / liver

4 endpoints

Secondary/registry result

Relative Percent Reduction in Liver Fat Percent

Time frame:Baseline, 40 weeks

Liver fat content, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	12.37	—
Placebo	-20.63	—

Secondary/registry result

Absolute Reduction in Liver Fat Percent

Time frame:Baseline, 40 weeks

Liver fat content, change

change from baseline, improvement

Posted result

Group	Value (mean), percentage of liver fat	95% CI
Liraglutide 3.0 mg	2.35	—
Placebo	-0.01	—

Secondary/protocol endpoint

Relative Percent Reduction in Liver Fat Percent

Time frame:Baseline, 40 weeks

MRI-PDFF, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Reduction in Liver Fat Percent

Time frame:Baseline, 40 weeks

Liver fat content, change

change from baseline, improvement

Heart failure

4 endpoints

Secondary/registry result

Relative Percent Change in Nt-proBNP

Time frame:Baseline, 40 weeks

NT-proBNP, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	12.10	—
Placebo	20.47	—

Secondary/registry result

Absolute Change in Nt-proBNP

Time frame:Baseline, 40 weeks

NT-proBNP, change

change from baseline, improvement

Posted result

Group	Value (mean), pg/mL	95% CI
Liraglutide 3.0 mg	-8.10	—
Placebo	1.44	—

Secondary/protocol endpoint

Relative Percent Change in Nt-proBNP

Time frame:Baseline, 40 weeks

NT-proBNP, change

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Change in Nt-proBNP

Time frame:Baseline, 40 weeks

NT-proBNP, change

change from baseline, improvement

Cardiometabolic biomarkers

12 endpoints

Secondary/registry result

Relative Percent Change in C-reactive Protein

Time frame:Baseline, 40 weeks

hs-CRP, change

percent change from baseline, improvement

LOINC 30522-7

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	-19.91	—
Placebo	19.02	—

Secondary/registry result

Relative Percent Change in Triglyceride/HDL-C Ratio

Time frame:Baseline, 40 weeks

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Liraglutide 3.0 mg	-2.10	—
Placebo	-2.18	—

Secondary/registry result

Absolute Change in CRP

Time frame:Baseline, 40 weeks

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Posted result

Group	Value (mean), mg/L	95% CI
Liraglutide 3.0 mg	-2.18	—
Placebo	-0.64	—

Secondary/registry result

Absolute Change in Triglyceride/HDL-C Ratio

Time frame:Baseline, 40 weeks

change from baseline, improvement

Posted result

Group	Value (mean), ratio	95% CI
Liraglutide 3.0 mg	-0.02	—
Placebo	-0.16	—

Secondary/registry result

Change From Baseline in Heart Rate

Time frame:Baseline, 40 weeks

Heart rate, change

change from baseline, improvement

Posted result

Group	Value (mean), beats per minute	95% CI
Liraglutide 3.0 mg	4.84	—
Placebo	2.67	—

Secondary/registry result

Change From Baseline in Blood Pressure

Time frame:Baseline, 40 weeks

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (mean), mmHg	95% CI
Liraglutide 3.0 mg	-5.84	—
Placebo	-0.02	—

Secondary/protocol endpoint

Relative Percent Change in C-reactive Protein

Time frame:Baseline, 40 weeks

hs-CRP, change

percent change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint

Relative Percent Change in Triglyceride/HDL-C Ratio

Time frame:Baseline, 40 weeks

percent change from baseline, improvement

Secondary/protocol endpoint

Absolute Change in CRP

Time frame:Baseline, 40 weeks

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint

Absolute Change in Triglyceride/HDL-C Ratio

Time frame:Baseline, 40 weeks

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Heart Rate

Time frame:Baseline, 40 weeks

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Blood Pressure

Time frame:Baseline, 40 weeks

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Safety / tolerability / PK

1 endpoint

Other_pre_specified/registry result

On-treatment Time, Weeks

Time frame:weeks

descriptive

Posted result

Group	Value (mean), weeks	95% CI
Liraglutide 3.0 mg	36.2	—
Placebo	36.1	—

Other (unclassified)

1 endpoint

Other/protocol endpoint/low confidence

On-treatment Time, Weeks

Time frame:weeks

descriptive

Publications (26)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
The lancet. Diabetes & endocrinology2021 Sep (month)PMID34358471doi:10.1016/S2213-8587(21)00179-0via clinicaltrials gov reference derived + pubmed nct search
Validation of a fast method for quantification of intra-abdominal and subcutaneous adipose tissue for large-scale human studies.
NMR in biomedicine2015 Dec (month)PMID26768490doi:10.1002/nbm.3432via CT.gov background
Predictive accuracy of single- and multi-slice MRI for the estimation of total visceral adipose tissue in overweight to severely obese patients.
NMR in biomedicine2015 May (month)PMID25808071doi:10.1002/nbm.3286via CT.gov background
BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening.
Diabetes care2015 Jan (month)PMID25538311doi:10.2337/dc14-2391via CT.gov background
The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study.
Journal of the American College of Cardiology2014 Sep 9PMID25190234doi:10.1016/j.jacc.2014.05.057via CT.gov background
Test-retest reliability of automated whole body and compartmental muscle volume measurements on a wide bore 3T MR system.
European radiology2014 Sep (month)PMID24871333doi:10.1007/s00330-014-3226-6via CT.gov background
American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2014 Sep (month)PMID25253227doi:10.4158/EP14280.PSvia CT.gov background
Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway.
Journal of the American College of Cardiology2014 Mar 25PMID24345592doi:10.1016/j.jacc.2013.11.035via CT.gov background
A pooled analysis of waist circumference and mortality in 650,000 adults.
Mayo Clinic proceedings2014 Mar (month)PMID24582192doi:10.1016/j.mayocp.2013.11.011via CT.gov background
MR quantification of total liver fat in patients with impaired glucose tolerance and healthy subjects.
PloS one2014 (year)PMID25343445doi:10.1371/journal.pone.0111283via CT.gov background
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
International journal of obesity (2005)2013 Nov (month)PMID23812094doi:10.1038/ijo.2013.120via CT.gov background
Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality.
Journal of the American College of Cardiology2013 Sep 3PMID23850922doi:10.1016/j.jacc.2013.06.027via CT.gov background
Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.
Obesity (Silver Spring, Md.)2013 Sep (month)PMID23687099doi:10.1002/oby.20135via CT.gov background
Relation of regional fat distribution to left ventricular structure and function.
Circulation. Cardiovascular imaging2013 Sep (month)PMID23929898doi:10.1161/CIRCIMAGING.113.000532via CT.gov background
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults.
JAMA2012 Sep 19PMID22990274doi:10.1001/2012.jama.11132via CT.gov background
Body fat distribution and risk of cardiovascular disease: an update.
Circulation2012 Sep 4PMID22949540doi:10.1161/CIRCULATIONAHA.111.067264via CT.gov background
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
International journal of obesity (2005)2012 Jun (month)PMID21844879doi:10.1038/ijo.2011.158via CT.gov background
Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity.
The Journal of clinical endocrinology and metabolism2011 Nov (month)PMID21865361doi:10.1210/jc.2011-0615via CT.gov background
Body-mass index and mortality among 1.46 million white adults.
The New England journal of medicine2010 Dec 2PMID21121834doi:10.1056/NEJMoa1000367via CT.gov background
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Lancet (London, England)2009 Nov 7PMID19853906doi:10.1016/S0140-6736(09)61375-1via CT.gov background
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
Arteriosclerosis, thrombosis, and vascular biology2008 Jun (month)PMID18356555doi:10.1161/ATVBAHA.107.159228via CT.gov background
The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study.
Journal of the American College of Cardiology2007 Aug 21PMID17707180doi:10.1016/j.jacc.2007.04.066via CT.gov background
Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis.
Diabetologia2007 Aug (month)PMID17549449doi:10.1007/s00125-007-0708-yvia CT.gov background
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary.
Critical pathways in cardiology2005 Dec (month)PMID18340209doi:10.1097/00132577-200512000-00018via CT.gov background
The metabolic syndrome--a new worldwide definition.
Lancet (London, England)2005 Sep 24-30 (month)PMID16182882doi:10.1016/S0140-6736(05)67402-8via CT.gov background
Human energy requirements: report of a joint FAO/ WHO/UNU Expert Consultation.
Food and nutrition bulletin2005 Mar (month)PMID15810802via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.